Back to Newsroom

Boston Business Journal: Bay State’s newest Nasdaq-listed biotech, Corbus gets $5M cystic fibrosis award

A year ago today, Corbus Pharmaceuticals didn’t exist. Today, it’s publicly-traded on the Nasdaq and planning to launch a mid-stage trial of a drug to treat cystic fibrosis by the end of June.

CEO Yuval Cohen of Corbus (Nasdaq: CRBP) says the speed at which the company has gotten up and running has a lot to do with the way it went public, which was not through a traditional initial public offering, nor a reverse merger into another publicly-traded firm.

Click here to read the full article